Isolation and identification of major metabolites of rifalazil in mouse and human

被引:11
作者
Mae, T [1 ]
Konishi, E [1 ]
Hosoe, K [1 ]
Hidaka, T [1 ]
机构
[1] Kaneka Corp, Takasago Res Labs, Takasago, Hyogo 6768688, Japan
关键词
D O I
10.1080/004982599237967
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Three metabolites of rifalazil have been isolated from dog urine and identified as 25-deacetyl-rifalazil, 30-hydroxy-rifalazil and 25-deacetyl-30-hydroxy-rifalazil. In the current study major metabolites of rifalazil in mouse and human were isolated and identified, and their antimicrobial activities determined. 2. Urinary excretion of rifalazil and its metabolites in six mouse strains, CD-1 (ICR), BALB/c, C57BL/6, C3H/He, DBA/2 and CBA/J, was examined. Two major metabolites were detected in mouse urine obtained after several oral doses, and the proportion of rifalazil metabolites against total urinary excretion varied over a 2-fold range (4.8-8.7 %) in the different mouse strains. 3. One of two major metabolites in mouse urine was 25-deacetyl-rifalazil and the other was unknown: it was isolated from mouse urine and identified by ms and H-1- and C-13-nmr as 32-hydroxy-rifalazil. 4. In human, two major metabolites of rifalazil were detected in urine obtained after administration of a single oral dose. These metabolites were also produced by incubation of rifalazil with pooled human liver microsomes, and identified by lc/ms and lc/ms/ms as 25-deacetyl-rifalazil and 32-hydroxy-rifalazil. 5. The antimicrobial activities of 32-hydroxy-rifalazil against Gram-positive bacteria and mycobacteria were similar with those of the parent compound.
引用
收藏
页码:1073 / 1087
页数:15
相关论文
共 20 条
[1]   Evaluation of in vivo therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, in SCID mouse model for disseminated Mycobacterium avium complex infection [J].
Emori, M ;
Tomioka, H ;
Sato, K ;
Saito, H .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1998, 10 (01) :59-65
[2]   THERAPEUTIC EFFICACY OF THE BENZOXAZINORIFAMYCIN KRM-1648 AGAINST EXPERIMENTAL MYCOBACTERIUM-AVIUM INFECTION INDUCED IN RABBITS [J].
EMORI, M ;
SAITO, H ;
SATO, K ;
TOMIOKA, H ;
SETOGAWA, T ;
HIDAKA, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :722-728
[3]   IN-VITRO AND IN-VIVO ANTIBACTERIAL ACTIVITIES OF KRM-1648 AND KRM-1657, NEW RIFAMYCIN DERIVATIVES [J].
FUJII, K ;
TSUJI, A ;
MIYAZAKI, S ;
YAMAGUCHI, K ;
GOTO, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (05) :1118-1122
[4]   IN-VITRO AND IN-VIVO ACTIVITIES OF THE BENZOXAZINORIFAMYCIN KRM-1648 AGAINST MYCOBACTERIUM-TUBERCULOSIS [J].
HIRATA, T ;
SAITO, H ;
TOMIOKA, H ;
SATO, K ;
JIDOI, J ;
HOSOE, K ;
HIDAKA, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (10) :2295-2303
[5]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF 3'-HYDROXY-5'-(4-ISOBUTYL-1-PIPERAZINYL)BENZOXAZINORIFAMYCIN (KRM-1648) AND ITS DEACETYL METABOLITE IN PLASMA, WHOLE-BLOOD, URINE AND TISSUE SAMPLES IN RATS [J].
HOSOE, K ;
KONISHI, E ;
HIDAKA, T ;
YAMANE, T ;
YAMASHITA, K ;
OHASHI, T .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 653 (02) :177-186
[6]   Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs [J].
Hosoe, K ;
Mae, T ;
Konishi, E ;
Fujii, K ;
Yamashita, K ;
Yamane, T ;
Hidaka, T ;
Ohashi, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2749-2755
[7]   Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog [J].
Hosoe, K ;
Mae, T ;
Yamashita, K ;
Fujii, K ;
Yamane, T ;
Hidaka, T ;
Ohashi, T .
XENOBIOTICA, 1996, 26 (03) :321-332
[8]   ACTIVITIES OF THE BENZOXAZINORIFAMYCIN KRM-1648 AND ETHAMBUTOL AGAINST MYCOBACTERIUM-AVIUM COMPLEX IN-VITRO AND IN MACROPHAGES [J].
INDERLIED, CB ;
BARBARABURNHAM, L ;
WU, M ;
YOUNG, LS ;
BERMUDEZ, LEM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (08) :1838-1843
[9]   Low-dose aerosol infection model for testing drugs for efficacy against Lycobacterium tuberculosis [J].
Kelly, BP ;
Furney, SK ;
Jessen, MT ;
Orme, IM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2809-2812
[10]   ACTIVITY OF KRM-1648, A NEW BENZOXAZINORIFAMYCIN, AGAINST MYCOBACTERIUM-TUBERCULOSIS IN A MURINE MODEL [J].
KLEMENS, SP ;
GROSSI, MA ;
CYNAMON, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (10) :2245-2248